Scope of the GLP Agonist Pipeline Report Coverage : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Key GLP Agonist Companies : Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou, Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics, Viking Therapeutics, Biolexis Therapeutics, and others Key GLP Agonist Pipeline Therapies : XW014, Survodutide, MK-6024, ECC5004, RGT001-075, Tirzepatide, CT 388, Pegylated exenatide, VK2735, MLX 7000, and others Dive deep into rich insights for new GLP agonists, visit @ GLP Agonist Drugs Table of Contents For further information on the GLP agonist pipeline therapeutics, reach out @ GLP Agonist Therapeutics Related Reports Obesity Pipeline Insight 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key obesity companies, including 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma , among others
The Bottom Line At its core, GLP-1 weight loss represents a different philosophy
The 2022 NEJM study, which showed sustained and significant weight loss with tirzepatide, primarily focused on people with obesity, not excess weight (pre-obesity)
Fiber from chicory root is another consumer-friendly solution that helps reduce sugar, improve nutrition, and enhance texture in snacks and bakery products
Tirzepatide slows gastric emptying, which affects the absorption of oral medications
Based on what we know from similar drugs, weight regain is likely without sustained lifestyle changes
